PK MED

About the company

PK MED is a French innovative biotech company, privately owned and established in 2019 with the support of Truffle Capital, a prominent European Venture Capital firm specializing in Life sciences.

PK MED specializes in the innovative development of custom-designed, injectable, and biodegradable micro-implants. Their expertise spans across critical healthcare domains, focusing on local drug delivery systems for rheumatology (PKM-01) and enhancing cell-homing techniques to improve bone marrow transplantation outcomes (PKM-02).

About the solution

Lead product candidate PKM-01 is developed to treat gout, an excruciating and increasingly prevalent form of arthritis. Today, approved products take time to partially alleviate pain and come with real safety risks.
PKM-01 is a drug combination product (sustained release formulation of the anti-inflammatory drug, colchicine, and an anesthetic) to be injected in the effected joint. PKM-01 is designed to be a new treatment paradigm in gout flares – a safe and very effective pain killer providing relief within minutes.

Website

Key information

– Therapeutic areas: Rheumatology, Bone marrow transplantation

– Based in: Headquarter : Paris (FRANCE) R&D : Lyon (FRANCE)

– Employees: 1-10

– Created in: 2019

HTL BIOTECHNOLOGY

About the company

HTL Biotechnology is a French biotech company and world leader in the development and responsible bioproduction of pharmaceutical-grade biopolymers. These biopolymers are used by healthcare companies for the development of treatments in a wide range of leading therapeutic areas such as ophthalmology, dermatology, medical aesthetics, and rheumatology.

For over 30 years, HTL Biotechnology has been a driving force for innovation in the sector, collaborating with research entities and biotech companies to address tomorrow’s medical needs (regenerative medicine, drug delivery, etc.).

Historically based in France, the company combines production, innovation, R&D and quality activities on its site. To meet the world’s growing need for biopolymers, the company has a subsidiary in Asia. HTL has been expanding in several countries, in particular to the US, where HTL is building a production facility and has a R&D lab.
HTL Biotechnology employs nearly 300 people worldwide.

About the solution

Biopolymers are at the heart of today’s and tomorrow’s therapeutic innovations, HTL Biotechnology offers:

Their current portfolio includes: hyaluronic acid and polynuleotides pharma-grade, sodium DNA cosmetic-grade

Their development portfolio includes : collagen (rhCOL3), heparosan, functionalized hyaluronic acid

Website

Key information

– Main industry type: Biotech

– Therapeutic areas: Ophthalmology, Medical Aesthetics, Rheumatology, Regenerative Medicine

– Based in: Javené (France) ; R&D Lab in New Jersey (US)

– Employees: 201 – 500

– Created in: 1992